Company: PCRX
Filing Date: 2025-03-14
Form Type: DEFA14A
Source: 0001104659-25-024033
Chunk: 7

Company: Pacira BioSciences, Inc.
Filing Date: 2025-03-14
Form: DEFA14A
Chunk 7
---
 and drive future growth for many years to come.

I want to emphasize that DOMA’s announcement—which contains
purposeful misstatements, a common occurrence in communications like this—has on our operations, your day-to-day
responsibilities, or our priorities. It is business as usual at Pacira as we continue to advance our important mission to deliver innovative,
non-opioid pain therapies to transform the lives of patients.

In the meantime, if you receive any inquiries from members of the
media or other stakeholders, please forward them to Susan Mesco, VP, Investor Relations () or Amber Sears, SVP, Communications and Public Affairs ().

Thank you for all that you do. Together we’ll continue to prove
that Better is Possible in the market, for patients, and for Pacira.

Best,

Frank

Forward-Looking Statements

Any statements in this document about Pacira’s future
expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,”
“anticipates,” “plans,” “estimates,” “expects,” “intends,”
“may,” “will,” “would,” “could,” “can” and similar expressions,
constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements
related to: the 2025 Annual Meeting, ‘5x30’, Pacira’s growth and business strategy; Pacira’s future outlook,
Pacira’s intellectual property and patent terms, Pacira’s growth and future operating results and trends, Pacira’s
strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential,
including Pacira’s plans with respect to the repayment of Pacira’s indebtedness, anticipated product portfolio,
development programs, development of products, strategic alliances and other statements that are not historical facts. For this
purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. Pacira cannot
assure you that its estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among
others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio; risks associated with
acquisitions